Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Clinical trial NCT04608318 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04608318
Sponsor: German CLL Study Group
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Lymphoid Leukemia

Start date: 2021-03-01
Primary completion: 2027-09-01
Enrollment: 897

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.